US 12,247,222 B2
Quality assurance of chondrocytes
Evy Lundgren Åkerlund, Bjarred (SE); and Katarzyna Chmielarska Masoumi, Lund (SE)
Assigned to Xintela AB, Lund (SE)
Filed by Xintela AB, Lund (SE)
Filed on Jun. 21, 2023, as Appl. No. 18/338,437.
Application 16/994,193 is a division of application No. 16/387,172, filed on Apr. 17, 2019, granted, now 10,781,424, issued on Sep. 22, 2020.
Application 18/338,437 is a continuation of application No. 16/994,193, filed on Aug. 14, 2020, granted, now 11,725,188.
Application 16/387,172 is a continuation of application No. PCT/EP2018/067580, filed on Jun. 29, 2018.
Claims priority of application No. 1750849-0 (SE), filed on Jun. 29, 2017.
Prior Publication US 2023/0348857 A1, Nov. 2, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/077 (2010.01); C12N 5/00 (2006.01); C12Q 1/6851 (2018.01); G01N 33/68 (2006.01)
CPC C12N 5/0655 (2013.01) [C12N 5/0018 (2013.01); C12N 5/0068 (2013.01); C12Q 1/6851 (2013.01); G01N 33/6887 (2013.01); C12N 2500/38 (2013.01); C12N 2501/58 (2013.01); C12N 2501/585 (2013.01); C12N 2513/00 (2013.01); G01N 2333/70546 (2013.01)] 21 Claims
 
1. A method for determining quality of a composition comprising isolated and cultured chondrocytes, wherein the quality determination comprises one or more of: identity of the chondrocytes, differentiation state of the chondrocytes, purity of the chondrocytes, and potency of the chondrocytes, the method comprising:
a) providing a candidate composition comprising isolated and cultured chondrocytes;
b) detecting the expression levels of integrin alpha10 and integrin alpha11 in said composition;
c) comparing the expression level of integrin alpha10 to the expression level of integrin alpha11; and
d) determining the ratio of integrin alpha10 expression to integrin alpha11 expression;
wherein detecting an integrin alpha10 to integrin alpha11 expression ratio of at least 4 to 1 is indicative of chondrocytic identity of the chondrocytes in the composition, differentiated state of the chondrocytes in the composition, purity of the chondrocytes in the composition, and/or potency of the chondrocytes of the composition, and thereby is indicative of a high quality chondrocyte composition.